Hefei Hengxin Life Science and Technology Co., Ltd. (SHE:301501)
China · Delayed Price · Currency is CNY 33.68
+0.11 (0.33%)
May 7, 2026, 3:04 PM CST
SHE:301501 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,876 | 1,845 | 1,562 | 1,396 | 1,054 | 696.15 |
Other Revenue | - | - | 32.16 | 29.51 | 33.89 | 22.75 |
| 1,876 | 1,845 | 1,594 | 1,425 | 1,088 | 718.9 | |
Revenue Growth (YoY) | 11.97% | 15.72% | 11.87% | 30.95% | 51.38% | 69.37% |
Cost of Revenue | 1,449 | 1,402 | 1,178 | 1,023 | 786.93 | 524.89 |
Gross Profit | 427.79 | 442.78 | 416.43 | 401.63 | 301.34 | 194.01 |
Selling, General & Admin | 134.88 | 132.6 | 100.28 | 93.46 | 70.71 | 51.85 |
Research & Development | 52.63 | 52.84 | 53.31 | 44.21 | 35.91 | 32.15 |
Other Operating Expenses | 1.93 | 2.5 | 6.93 | 6.04 | 4.29 | 4.23 |
Operating Expenses | 189.44 | 187.94 | 161.4 | 146.94 | 113.04 | 88.65 |
Operating Income | 238.35 | 254.84 | 255.03 | 254.69 | 188.3 | 105.36 |
Interest Expense | - | - | -10.03 | -5.31 | -4.41 | -2.62 |
Interest & Investment Income | 1.46 | 1.04 | 2.35 | 3.01 | 1.66 | 1.03 |
Earnings From Equity Investments | - | - | -0 | - | - | - |
Currency Exchange Gain (Loss) | - | - | -5.91 | 3.65 | 7.03 | -2.4 |
Other Non Operating Income (Expenses) | -8.9 | 34.32 | 11.38 | -0.39 | -0.33 | -0.26 |
EBT Excluding Unusual Items | 230.92 | 290.2 | 252.82 | 255.65 | 192.25 | 101.11 |
Gain (Loss) on Sale of Investments | 5.77 | 4.64 | - | -2.14 | -5.5 | -11.29 |
Gain (Loss) on Sale of Assets | -0.26 | 0.34 | 0.88 | -0.3 | 0.24 | 0.05 |
Asset Writedown | -6.51 | -5.71 | -0.51 | -2.41 | -1.17 | -0.01 |
Other Unusual Items | - | - | 8.04 | 7.2 | 6.08 | 4.08 |
Pretax Income | 229.92 | 289.46 | 261.24 | 258.01 | 191.91 | 93.94 |
Income Tax Expense | 48.6 | 56.86 | 34.43 | 36.56 | 25.95 | 12.86 |
Earnings From Continuing Operations | 181.32 | 232.6 | 226.81 | 221.46 | 165.95 | 81.08 |
Minority Interest in Earnings | -7.05 | -8.76 | -6.92 | -7.59 | -3.19 | -0.92 |
Net Income | 174.27 | 223.84 | 219.89 | 213.86 | 162.77 | 80.16 |
Net Income to Common | 174.27 | 223.84 | 219.89 | 213.86 | 162.77 | 80.16 |
Net Income Growth | -31.98% | 1.80% | 2.82% | 31.39% | 103.04% | 207.30% |
Shares Outstanding (Basic) | 141 | 139 | 111 | 111 | 111 | 105 |
Shares Outstanding (Diluted) | 141 | 139 | 111 | 111 | 111 | 105 |
Shares Change (YoY) | 19.60% | 24.81% | 0.31% | -0.04% | 5.81% | - |
EPS (Basic) | 1.24 | 1.61 | 1.98 | 1.93 | 1.47 | 0.77 |
EPS (Diluted) | 1.24 | 1.61 | 1.98 | 1.93 | 1.47 | 0.77 |
EPS Growth | -43.13% | -18.44% | 2.50% | 31.45% | 91.90% | - |
Free Cash Flow | -181.84 | -188.4 | -78.83 | -110.86 | 2.58 | 9.75 |
Free Cash Flow Per Share | -1.29 | -1.36 | -0.71 | -1.00 | 0.02 | 0.09 |
Dividend Per Share | - | - | 0.345 | - | - | - |
Gross Margin | 22.80% | 24.00% | 26.12% | 28.18% | 27.69% | 26.99% |
Operating Margin | 12.70% | 13.81% | 16.00% | 17.87% | 17.30% | 14.66% |
Profit Margin | 9.29% | 12.13% | 13.79% | 15.01% | 14.96% | 11.15% |
Free Cash Flow Margin | -9.69% | -10.21% | -4.95% | -7.78% | 0.24% | 1.36% |
EBITDA | 345.52 | 354.07 | 322.51 | 297.44 | 221.74 | 129.15 |
EBITDA Margin | 18.41% | 19.19% | 20.23% | 20.87% | 20.38% | 17.96% |
D&A For EBITDA | 107.17 | 99.23 | 67.48 | 42.75 | 33.43 | 23.79 |
EBIT | 238.35 | 254.84 | 255.03 | 254.69 | 188.3 | 105.36 |
EBIT Margin | 12.70% | 13.81% | 16.00% | 17.87% | 17.30% | 14.66% |
Effective Tax Rate | 21.14% | 19.65% | 13.18% | 14.17% | 13.52% | 13.69% |
Revenue as Reported | - | - | 1,594 | 1,425 | 1,088 | 718.9 |
Advertising Expenses | - | - | - | 2 | 0.55 | 1.16 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.